Product Pipeline

Future Products

CYBIS 10:25

Pharmaceutical

  • Chronic Pain Formulation
  • THC + CBD + compounds
  • Clinical Development Programme
  • Administration: Oral solution
  • Full spectrum
  • Patient target: 2nd line therapy for chronic non cancer pain.

CYM-001

Pharmaceutical

  • Anxiety Formulation
  • CBD + specific formulated compounds
  • International ARTG registration and export
  • Administration: Oral solution
  • Full spectrum
  • Patient target: Highly Anxiolytic patients 

CYM-004

Pharmaceutical
(no THC)

  • Anxiety Formulation
  • CBD + specific formulated compounds
  • International ARTG registration and export
  • Administration: Oral solution
  • Full spectrum
  • Patient target: Highly Anxiolytic patients
cymra-icon

Cymra’s Pharmaceutical Experience and IP in regards to product and formulation development, clinical programs and regulatory pathways provides us a unique advantage over non pharmaceutical companies.

Note: All dates and products are provided as an estimate, supply times and products may vary.